Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.
1Transplant, Recanati/Miller Transplantation Institute, New York, NY
2Surgery, Mount Sinai Medical Center, New York, NY.
Meeting: 2016 American Transplant Congress
Abstract number: B84
Keywords: Donation, Nephrectomy, Outcome, Renal function
Session Information
Session Name: Poster Session B: Donor Management: All Organs
Session Type: Poster Session
Date: Sunday, June 12, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: The benefit and short-term safety have been established in previous studies; however, the risk of bleeding and long-term renal impairment in patients undergoing donor nephrectomy remain unclear. We report our experience at a high volume transplant center.
Method: Laparoscopic donor nephrectomy was performed in 874 patients between 01/1996-01/2014. Intravenenous ketorolac was administered within 30 mins of completion of the surgical procedure at a dose of 30 mg every 6 hours. Patients were categorized into the ketorolac group(n=373) vs. non-ketorolac group(n=501). Primary outcomes were changes in serum creatitine and hemoglobin levels. Poor outcome was defined as surgical complications.
Results: Mean donor age was 39 years and 371(42.4%) were male. Left kidneys were procured in 67%. Operative time averaged 217 mins, and WIT 162 sec. Baseline demographic and operative outcomes were comparable in both groups. No statistically significant differences were found between the ketorolac group and non-ketorolac group in preoperative and postoperative hemoglobin levels and serum creatinine at 1 week, 1 year, and 5 years (p=NS)
|
Variables |
Group 1Ketorolac N=373 |
Group 2Non-ketorolac N=501 |
P-value |
|
Age (mean +-SD) |
38.5(11.4) |
39.3(11.4) |
0.283 |
|
Prior abdominal surgery(%) |
26.7 |
26.7 |
0.989 |
|
Mean BMI |
26.6(4.0) |
27.2(4.8) |
0.162 |
|
Operative time(mins), mean(SD) |
202.6(56.9 |
223.8(57.8) |
<0.001 |
|
Estimated blood loss(ml), mean(SD) |
94.3(82.8) |
160.8(155.4) |
<0.001 |
|
Length of stay(days) |
2.4(1.6) |
2.6(1.1) |
0.055 |
|
Laboratory values (1 week) mean(SD) |
|
|
|
|
Creatinine(mg/dL) |
1.3(1.1) |
1.3(0.4) |
0.801 |
|
Hemoglogin(g/dL) |
12.9(1.5) |
13.4(1.4) |
0.05 |
|
Laboratory values at 1 yr mean (SD) |
|
|
|
|
Creatinine(mg/dL) |
1.3(1.1) |
1.2(0.4) |
0.347 |
|
Hemoglogin(g/dL) |
13.3(1.3) |
13.3(1.5) |
0.899 |
|
Laboratory values at 5 yrs mean(SD) |
|
|
|
|
Creatinine(mg/dL) |
1.0(0.0) |
1.1(0.3) |
0.343 |
|
Hemoglogin(g/dL) |
13.0(2.2) |
12.7(1.3) |
0.686 |
. Ketorolac use was not associated with poor outcome (p=NS).
Conclusion: The use of intravenous ketorolac in patients undergoing donor nephrectomy appears to be safe and was not associated with an increased risk of bleeding and renal impairment.
CITATION INFORMATION: Tabrizian P, Giacca M, Prigoff J, Chin E, Palese M, Herron D, Arvelakis A, LaPointe Rudow D, Florman S, Shapiro R. Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Tabrizian P, Giacca M, Prigoff J, Chin E, Palese M, Herron D, Arvelakis A, Rudow DLaPointe, Florman S, Shapiro R. Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-safety-of-intravenous-ketorolac-use-after-donor-nephrectomy/. Accessed May 11, 2025.« Back to 2016 American Transplant Congress